BIBF1120

nintedanib · Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BIBF1120, covering 2017-11-01 to 2017-11-01. Get the full timeline:

Most recent: Clinical Trial Update: NOA-12: BIBF1120 and R-RT in Glioblastoma [Phase 1, Phase 2]